PDCD1 and neoplasm: Moreover, RNA-seq of 7-day treated tumours indicated an enrichment of IFN and inflammatory-related pathways in tumours treated with combination of RMC-4998, RMC-4550 and anti-PD-1 compared to dual-targeted therapy (Fig. 7d).